Cargando…

Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population

BACKGROUND: Knowledge of the vaccine effectiveness (VE) of a third or booster vaccine dose in preventing SARS-CoV-2 infection or its consequences is critical in developing recommendations for their use. We determined relative VE of 3 vs 2 doses of an mRNA vaccine in preventing symptomatic SARS-CoV-2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Butt, Adeel A, Talisa, Victor B, Yan, Peng, Shaikh, Obaid S, Omer, Saad B, Mayr, Florian B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903438/ https://www.ncbi.nlm.nih.gov/pubmed/35245940 http://dx.doi.org/10.1093/cid/ciac178

Ejemplares similares

Comparative COVID-19 Vaccine Effectiveness Over Time in Veterans
por: Mayr, Florian B, et al.
Publicado: (2022)

Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination
por: Butt, Adeel A., et al.
Publicado: (2021)

Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination in a high-risk national population
por: Butt, Adeel A., et al.
Publicado: (2021)

COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periods
por: Mayr, Florian B., et al.
Publicado: (2022)

Variation in Clinical Treatment and Outcomes by Race Among US Veterans Hospitalized With COVID-19
por: Castro, Alexander D., et al.
Publicado: (2022)

Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans
por: Mayr, Florian B., et al.
Publicado: (2022)

Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine
por: Mwimanzi, Francis, et al.
Publicado: (2023)

Adverse Events Following Immunization With mRNA and Viral Vector Vaccines in Individuals With Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection From the Canadian National Vaccine Safety Network
por: Bettinger, Julie A, et al.
Publicado: (2022)

Pregnancy Status at the Time of Coronavirus Disease 2019 Vaccination and Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Magnus, Maria C, et al.
Publicado: (2022)

Effectiveness of a Second Dose of an mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in Individuals Previously Infected by Other Variants
por: Monge, Susana, et al.
Publicado: (2022)

Impact of Vaccination With the SCB-2019 Coronavirus Disease 2019 Vaccine on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Household Contact Study in the Philippines
por: Tadesse, Birkneh Tilahun, et al.
Publicado: (2022)

Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine
por: Leung, Nancy H L, et al.
Publicado: (2022)

Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses
por: Lawrenz, Jan, et al.
Publicado: (2022)

Getting Personal: How Childhood Vaccination Policies Shape the Landscape of Vaccine Exemptions
por: Garnier, Romain, et al.
Publicado: (2020)

Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada
por: Skowronski, Danuta M, et al.
Publicado: (2022)

Multiregional Population-Based Cohort Study for Evaluation of the Association Between Herpes Zoster and mRNA Vaccinations for Severe Acute Respiratory Syndrome Coronavirus-2: The VENUS Study
por: Ishiguro, Chieko, et al.
Publicado: (2023)

Severe Acute Respiratory Syndrome Coronavirus 2 Delta Vaccine Breakthrough Transmissibility in Alachua County, Florida
por: Rife Magalis, Brittany, et al.
Publicado: (2022)

Association of Cytomegalovirus Serostatus With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responsiveness in Nursing Home Residents and Healthcare Workers
por: Freeman, Michael L, et al.
Publicado: (2023)

A Small but Significantly Greater Incidence of Inflammatory Heart Disease Identified After Vaccination for Severe Acute Respiratory Syndrome Coronavirus 2
por: Knowlton, Kirk U, et al.
Publicado: (2021)

Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial
por: Speich, Benjamin, et al.
Publicado: (2022)

Description of Hospitalizations due to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Based on Vaccination Status
por: Moffa, Matthew A, et al.
Publicado: (2022)

Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada
por: Skowronski, Danuta M, et al.
Publicado: (2022)

Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
por: El Sahly, Hana M, et al.
Publicado: (2022)

Herpes Zoster Reactivation After mRNA and Adenovirus-Vectored Coronavirus Disease 2019 Vaccination: Analysis of National Health Insurance Database
por: Yoon, Jin Gu, et al.
Publicado: (2023)

Relative Virulence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Vaccinated and Unvaccinated Individuals Hospitalized With SARS-CoV-2
por: Grima, Alicia A, et al.
Publicado: (2022)

Early Introduction and Rise of the Omicron Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant in Highly Vaccinated University Populations
por: Petros, Brittany A, et al.
Publicado: (2022)

Development of an Effective Immune Response in Adults With Down Syndrome After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination
por: Esparcia-Pinedo, Laura, et al.
Publicado: (2022)

SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada
por: El Adam, Shiraz, et al.
Publicado: (2022)

Severe Acute Respiratory Syndrome Coronavirus 2: Vaccine Hesitancy Among Underrepresented Racial and Ethnic Groups With HIV in Miami, Florida
por: Jones, Deborah L, et al.
Publicado: (2021)

Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
por: Maeda, Haruka, et al.
Publicado: (2022)

Quantification and Progress Over Time of Specific Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 in Breast Milk of Lactating Women Vaccinated With BNT162b2 Pfizer-BioNTech Coronavirus Disease 2019 Vaccine (LacCOVID)
por: Esteve-Palau, Erika, et al.
Publicado: (2022)

Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study
por: Corradini, Paolo, et al.
Publicado: (2022)

Distinct Homologous and Variant-Specific Memory B-Cell and Antibody Response Over Time After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccination( )
por: Haralambieva, Iana H, et al.
Publicado: (2022)

Association Between Cycle Threshold Value and Vaccination Status Among Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Cases in Ontario, Canada, in December 2021
por: Ravindran, Saranyah, et al.
Publicado: (2023)

Host Predictors of Broadly Cross-Reactive Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern Differ Between Infection and Vaccination
por: Tang, Li, et al.
Publicado: (2021)

Differential Severe Acute Respiratory Syndrome Coronavirus 2–Specific Humoral Response in Inactivated Virus–Vaccinated, Convalescent, and Breakthrough-Infected Subjects
por: Duarte, Luisa F, et al.
Publicado: (2023)

Adenovirus-Based Vaccines and Thrombosis in Pregnancy: A Systematic Review and Meta-analysis( )
por: Pischel, Lauren, et al.
Publicado: (2022)

Binding and Avidity Signatures of Polyclonal Sera From Individuals With Different Exposure Histories to Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Vaccination, and Omicron Breakthrough Infections
por: Singh, Gagandeep, et al.
Publicado: (2023)

Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination
por: Jongkees, Marlou J, et al.
Publicado: (2022)

Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees
por: Jacobson, Mark A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ufjo4uj2knth0thn8srn1jnlfn